NCT04302766 (ClinicalTrials.gov) |
Arm A: remdesivir |
Unspecified |
Unspecified |
Unspecified |
Available |
USA |
NCT04292899 (ClinicalTrials.gov) |
Arm A: remdesivir Arm B: standard
treatment |
400 |
Yes |
No |
Recruiting |
USA and Asia |
NCT04292730 (ClinicalTrials.gov) |
Arm A: remdesivir Arm B: standard
treatment |
600 |
Yes |
No |
Recruiting |
USA and Asia |
NCT04280705 (ClinicalTrials.gov) |
Arm A: remdesivir Arm B: placebo |
394 |
Yes |
Double |
Recruiting |
USA and South Korea |
2020-000841-15 (EU-CTR) |
Arm A: remdesivir Arm B: standard treatment |
400 |
Yes |
No |
Recruiting |
Worldwide |
2020-000842-32 (EU-CTR) |
) Arm A: remdesivir Arm B: standard treatment |
600 |
Yes |
No |
Recruiting |
Worldwide |
NCT04252664 (ClinicalTrials.gov) |
Arm A: remdesivir Arm B: placebo |
308 |
Yes |
Quadruple |
Recruiting |
China |
NCT04257656 (ClinicalTrials.gov) |
Arm A: remdesivir Arm B: placebo |
453 |
Yes |
Quadruple |
Recruiting |
China |
NCT04315948 (ClinicalTrials.gov) |
Arm A: remdesivir Arm B:
lopinavir/ritonavir Arm C: lopinavir/ritonavir and interferon beta 1a
Arm D: hydroxychloroquine Arm E: standard treatment |
3100 |
Yes |
No |
Recruiting |
France |